Historical News

第一排 第二排 第三排 第四排

Taipei, Taiwan, 24 February 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced that it has filed a New Drug Application (“NDA”) under the 505(b)(2) regulator...

Solaxa and Alvogen enter into license agreement for the development and commercialization of SLX-100 for spinocerebellar ataxia type 27B (SCA27B)   Alvogen will acquire worldwide rights for SLX-100 for SCA27B and will be responsible for the co...

Planegg-Martinsried, Germany and Taipei, Taiwan, 11 February 2026 – Formycon AG (FWS: FYB, “Formycon”) and Lotus Pharmaceutical (“Lotus”) today announced the conclusion of an exclusive license agreement for Formycon&rsqu...

Taipei, Taiwan, 10 February 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenues for January 2026 of NT$2,052 million, repr...

Taipei, Taiwan, 20 January 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced the advancement of its Vietnam drug portfolio acquisition. Lotus had entered into an asset ...

Taipei, Taiwan, 12 January 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenues for December 2025 of NT$2,442 million, represent...

Taipei, Taiwan, 06 January 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced a significant milestone with the approval of VAZKEPA® (Icosapent Ethyl) by the Health S...

Taipei, Taiwan, 29 December 2025 — Lotus Pharmaceuticals (1795:TT; “Lotus” or “the Company”), a multinational pharmaceutical company, today announce its sponsor for the Street Medicine Program operated by the Charitable ...